Venous Thromboembolism (VTE) is a serious, preventable public health problem that requires timely treatment. Because signs and symptoms are non-specific, patients often present to primary care providers with VTE symptoms prior to diagnosis. Today there are no federal measurement tools in place to track delayed diagnosis of VTE. We developed and tested an electronic clinical quality measure (eCQM) to quantify Diagnostic Delay of Venous Thromboembolism (DOVE); the rate of avoidable delayed VTE events occurring in patients with a VTE who had reported VTE symptoms in primary care within 30 days of diagnosis. DOVE uses routinely collected EHR data without contributing to documentation burden. DOVE was tested in two geographically distant healthcare systems. Overall DOVE rates were 72.60% (site 1) and 77.14% (site 2). This novel, data-driven eCQM could inform healthcare providers and facilities about opportunities to improve care, strengthen incentives for quality improvement, and ultimately improve patient safety.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785865 | PMC |
JBJS Rev
January 2025
Department of Orthopaedic Surgery, University of California Davis, Sacramento, California.
» Patients with diabetes mellitus (DM) undergoing shoulder arthroplasty (SA) have a unique risk profile, which must be considered by clinicians.» The presence of DM as a comorbidity is associated with longer length of stay following SA, greater likelihood of nonhome discharge, and a higher rate of 90-day readmission.» Though the incidence is low, patients with DM are at an increased risk of serious postoperative cardiovascular complications, such as pulmonary embolism, venous thromboembolism, and myocardial infarction.
View Article and Find Full Text PDFNeurosurgery
February 2025
Global Neurosciences Institute, Philadelphia , Pennsylvania , USA.
Background And Objectives: Despite growing interest in how patient frailty affects outcomes (eg, in neuro-oncology), its role after transsphenoidal surgery for Cushing disease (CD) remains unclear. We evaluated the effect of frailty on CD outcomes using the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) data set from a collaboration of US academic pituitary centers.
Methods: Data on consecutive surgically treated patients with CD (2011-2023) were compiled using the 11-factor modified frailty index.
JAMA Surg
January 2025
Population Health Research Institute, Hamilton, Ontario, Canada.
Importance: Perioperative bleeding is common in general surgery. The POISE-3 (Perioperative Ischemic Evaluation-3) trial demonstrated efficacy of prophylactic tranexamic acid (TXA) compared with placebo in preventing major bleeding without increasing vascular outcomes in noncardiac surgery.
Objective: To determine the safety and efficacy of prophylactic TXA, specifically in general surgery.
Res Pract Thromb Haemost
January 2025
Thrombosis Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
Background: A high level of plasma coagulation factor (F)VIII is an established and likely causal risk factor for venous thromboembolism (VTE). Procoagulant phospholipids (PPLs) facilitate FVIII activity in coagulation.
Objectives: To assess the association between plasma levels of FVIII and risk of future VTE according to PPL clotting time (PPL), an inverse surrogate measure of plasma PPL activity.
Res Pract Thromb Haemost
January 2025
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Background: Venous thromboembolism (VTE) is a serious complication following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Despite improvements with fast-track treatment protocols, 0.5% of patients still develop a VTE within 90-days postoperatively.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!